Cutaneous Drug Eruptions Associated With the Use of New Oncological Drugs
TLDR New cancer drugs often cause skin and nail problems.
The document discussed the cutaneous side effects associated with new oncological drugs, highlighting that these drugs often caused skin, mucosa, and adnexa reactions. Common reactions included alopecia, skin pigmentation changes, and nail dystrophies. Specific drug classes like EGFR inhibitors frequently induced papulopustular rashes and other skin changes, while multikinase inhibitors often led to hand-foot syndrome. BRAF inhibitors were associated with rashes and cutaneous neoplasias, and MEK/ERK inhibitors caused similar toxicities to EGFR inhibitors. The document focused on the clinical presentation, histopathology, and treatment options for these side effects.
